Brief: SynAct Pharma: Approval Of Amended Study Protocol For Phase 2a Study In iMN
Sept 14 (Reuters) - SynAct Pharma AB SYNACT.ST :
* APPROVAL OF AMENDED STUDY PROTOCOL FOR THE PHASE 2A STUDY
IN IMN
Source text for Eikon: ID:nMFNbzF0x5
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development